Company database

A

argenx

Compare

Conducts multi-target oral macrocyclic peptide research with Unnatural Products. Evidence supporting marketed antibody products does not raise the evidence grade of the macrocycle program.

A

AstraZeneca

Compare

Entered chronic-disease macrocyclic peptide research through the Syneron Bio collaboration. No named clinical oral candidate from that collaboration has been disclosed.

NN

Novo Nordisk

Compare

Works with Orbis on oral macrocycle discovery and with Vivtex on delivery. Success with oral semaglutide does not automatically validate the collaborative macrocycle program.

SG6001 is an oral PCSK9 cyclic peptide. Official materials confirm a preclinical program and an out-licensing strategy; clinical status of other antifungal candidates is not applied to this program.

PT

Palatin Technologies

Compare

PL8177 is a colon-delivered cyclic heptapeptide MC1R agonist. The company reported Phase 2 UC proof of concept and explicitly welcomes partnerships / licensing.

D

Debiopharm

Compare

Alisporivir (Debio 025) is a cyclosporine-derived cyclophilin inhibitor with historical clinical development. A 2021 trial does not establish current active status.

X

XtalPi

Compare

PepiX™ connects AI, automated synthesis, and experimental screening. The website identifies oral cyclic peptides as a priority; food-peptide GRAS status is not pharmaceutical evidence.

H

HitGen

Compare

The company's interim report describes peptidomimetic macrocycle discovery, optimization, and oral applications. DEL and platform capabilities do not establish human oral evidence for proprietary candidates.

I

IRBM

Compare

Provides optimization of macrocyclic peptides derived from mRNA / phage display. Its website reports involvement in developing Merck's oral PCSK9 peptide MK-0616.

CT

Curve Therapeutics

Compare

Microcycle® functionally screens compact macrocycles in live cells and develops macrocycle-derived drugs. This review did not confirm a named oral cyclic peptide candidate.

Its peptide screening platform covers linear, cyclic, and helical structures, so it is included as an adjacent discovery capability. It is not automatically classified as a validated oral cyclic peptide drug developer.

T

Triastek

Compare

T25 is an oral octreotide acetate tablet. MED&SSE produces its shell and drug-containing core; FDA IND clearance was disclosed in 2026.

H

Henlius

Compare

Original company materials confirm cyclic peptides as a development modality. This review did not find a primary announcement sufficient to verify a specific oral candidate and its current stage.

SG

Sunshine Guojian

Compare

An investor record describes program 629 as an oral IL-23 cyclic peptide with PK suggesting once-weekly potential. Human results and the latest stage were not confirmed in this review.

SB

Sciwind Biosciences

Compare

The OralVantage™ oral peptide platform combines molecular stabilization and formulation strategies. It is included as a noncyclic peptide platform reference; validated oral cyclic peptides are not assumed.

Founded in 2026, this early-stage oral long-acting peptide company describes molecular design, microbial expression, and OMV packaging / delivery. Cyclic peptide identity and human evidence require verification.

BT

Bicycle Therapeutics

Compare

An important adjacent company in bicyclic peptide screening and conjugation. Its disclosed nonoral clinical pipeline is not evidence of oral cyclic peptide success.

H→

Hepion → Panetta Partners

Compare

Rencofilstat (CRV431) has oral clinical studies in MASH. Hepion transferred related assets to Panetta in 2025; the record preserves the historical development and change in rights.

ST

Sublimity Therapeutics / Sigmoid heritage

Compare

ST-0529 is an oral cyclosporine formulation for UC with historical Phase 2 registration. The Romanian record reviewed is marked prematurely ended. Current ownership and company status require verification.

SP

Sorriso Pharmaceuticals

Compare

SOR102 is a locally acting oral TNF / IL-23 bispecific single-domain antibody with a primary Phase 1 study. It is included as a noncyclic oral biologic reference.

DF

Dr. Falk Pharma

Compare

The ST-0529 oral cyclosporine Phase 2 registry lists the company as a study supporter. That regional record ended prematurely; current development rights or collaboration budgets are not inferred.

M/

Merck / MSD

Compare

LIPFENDRA is a U.S.-approved oral PCSK9 inhibitor. Its label confirms sodium caprate and approximately 1% oral bioavailability.

B

Bachem

Compare

Provides process development, analytical services, and GMP clinical manufacturing for cyclic peptides, stapled peptides, and peptidomimetics. Classified as a manufacturing service provider; client drugs are not treated as proprietary pipelines.

WA

WuXi AppTec / WuXi TIDES

Compare

The website describes a client case for a non-GLP-1 oral cyclic peptide, from library synthesis and lead optimization through GMP preparation. Only service capability is recorded; the unnamed client is neither identified nor guessed.